A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

To join this study, you would need to have a clear diagnosis of multiple myeloma that meets specific medical standards. Your general health and ability to perform daily activities would also be assessed, typically needing to be quite good. The study is for adults aged 18 and older, and it includes both men and women.

Critically, for some parts of the study, you must have already tried at least three different types of multiple myeloma treatments, including certain common medications like PIs, IMiDs, and anti-CD38 monoclonal antibodies. For other parts of the study, you would also need to have tried a treatment that targets something called BCMA.

There are also some reasons you wouldn't be able to join. For example, if you have other serious medical conditions like certain heart problems, lung issues needing oxygen, or certain infections (like HIV or hepatitis B/C). If you've recently had a stroke or seizure, or certain other types of blood cancers, you also wouldn't be able to participate. Also, you shouldn't have had other anti-cancer treatments too close to the start of the study.

If you decide to take part in this study, you would receive the new medicine, teclistamab. The study will involve regular visits to the clinic so the medical team can monitor your health and how you are responding to the treatment. This will include blood tests, physical examinations, and possibly other scans or checks to see the effect on your multiple myeloma. You would need to follow specific instructions about the medication and any other study rules. The total duration of your participation would depend on how you respond to the treatment and the study's design.